Sequencing Facility Uses Cutting-Edge Technology to Make the Old New Again

Photograph of Jyoti Shetty, Monika Mehta, and Yongmei Zhao in the Sequencing Facility.

Just a few years ago, it was difficult to get any meaningful sequence data from formalin-fixed, paraffin-embedded patient tissue samples. These biopsy specimens, which are tissues preserved in formaldehyde and embedded in wax for storage, are easy to make and store, even in remote research locations. Many are available, and more are made all the time, for use in experimental research and drug development. Because there are so many samples that have been taken over numerous years, they can also be used to help study the evolution of diseases and viruses.


Virtual Discussion Panel Provides Insights on Data Science

A graphic advertising the data science discussion panel.

A recent Data Science Discussion Panel, hosted virtually by the Scientific Library, provided more than 60 participants with expert insights about data science in cancer research from six members of Advanced Biomedical Computational Science (ABCS), part of the Biomedical Informatics and Data Science Directorate of the Frederick National Laboratory for Cancer Research.


Inside the War Room Against Drug-Resistant HIV

Steve Hughes, Ph.D., compares HIV research to a war. He and his colleagues are entrenched on a microscopic battlefield, fighting a conflict where seemingly small victories could mean a leap forward. Right now, they are grappling with the emergence of HIV strains resistant to existing antiretroviral drugs, medicines that suppress the virus in people living with HIV.


Serendipitous Collaboration Leads to Potential Therapy for Liver Cancer

Colorized image of killer T cells

The old adage that says two heads are better than one certainly seems true for Mitchell Ho, Ph.D., a senior investigator in the Center for Cancer Research, and Xiaolin Wu, Ph.D., a principal scientist in the Genomics Technology Laboratory, a CCR Core at the Frederick National Laboratory. Together, these two scientists are using next-generation genomics technology to develop, in an animal model, a chimeric antigen receptor T-cell therapy that might help patients with hepatocellular carcinoma, the most common type of liver cancer.



Subscribe to Science